Figure 3From: Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudyBaseline bone mineral density (BMD) and breast cancer recurrence. Incidence of breast cancer recurrence with tibolone or placebo according to baseline BMD. Significantly more breast cancers occurred in women with normal BMD taking tibolone (15.6%) compared with either osteopenic or osteoporotic patients (7.3% and 7.7%, respectively; P ≤ 0.016).Back to article page